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Abstract
Mitochondria are well-known cellular organelles that play a vital role in cellular bioenergetics, 
heme biosynthesis, thermogenesis, calcium homeostasis, lipid catabolism, and other metabolic 
activities. Given the extensive role of mitochondria in cell function, mitochondrial dysfunction 
plays a part in many diseases, including diabetes and Alzheimer’s disease (AD). In most cases, 
there is overwhelming evidence that impaired mitochondrial function is a causative factor in these 
diseases. Studying mitochondrial function in diseased cells vs healthy cells may reveal the 
modified mechanisms and molecular components involved in specific disease states. In this 
chapter, we provide a concise overview of the major recent findings on mitochondrial 
abnormalities and their link to synaptic dysfunction relevant to neurodegeneration and cognitive 
decline in AD and diabetes. Our increased understanding of the role of mitochondrial perturbation 
indicates that the development of specific small molecules targeting aberrant mitochondrial 
function could provide therapeutic benefits for the brain in combating aging-related dementia and 
neurodegenerative diseases by powering up brain energy and improving synaptic function and 
transmission.
1. INTRODUCTION
Emerged evidence suggests that the deleterious and advanced cellular changes in aging and 
diabetes are linked to mitochondrial dysfunction.1,2 Brain aging is often characterized by 
neuronal loss and synaptic alteration, which are associated with mitochondrial 
abnormalities, energy failure, respiratory chain impairment, generation of reactive oxygen 
species (ROS), and neuronal perturbation.3 Further, various evidences suggest that 
mitochondrial dysfunction is a prominent and early oxidative stress-associated factor that 
produces neuronal abnormalities in aging and diabetes, resulting in susceptibility to aging-
related neurodegenerative diseases.4 In the neurons, mitochondria are distributed throughout 
the length of the axons, presynaptic terminals, and dendrites. Mitochondria play active roles 
in regulating synaptogenesis and morphological/functional responses to synaptic activity; 
thus, mitochondrial dysfunction can lead to a stark neuronal energy deficit and, in the long 
run, to modifications in neuronal synapses and neurodegeneration in the aging brain.1
Alzheimer’s disease (AD) is a chronic aging-related disease with two pathological features: 
abnormal accumulations of amyloid beta peptide (Aβ) and phosphorylation of tau protein in 
1Corresponding author: shidu@ku.edu. 
HHS Public Access
Author manuscript
Prog Mol Biol Transl Sci. Author manuscript; available in PMC 2018 April 12.
Published in final edited form as:













the brain. Increased evidence indicates that mitochondrial and synaptic dysfunction is an 
early pathological feature of AD.5 Aβ has deleterious effects on mitochondrial function and 
structure and contributes to energy failure, respiratory chain impairment, ROS generation, 
induction of mitochondrial permeability transition pore (mPTP), imbalance of calcium 
homeostasis, disruption of mitochondrial dynamics, and mitochondrial DNA/RNA 
mutations.6 Although Aβ directly and indirectly causes abnormal mitochondrial and 
neuronal function, recent studies have highlighted the association between early 
mitochondrial dysfunction and the accumulation of Aβ in mitochondria, implicating 
mitochondrial Aβ in AD pathogenesis.7–28 These observations provide a better 
understanding of the relationship between mitochondria and AD pathogenesis.
Mitochondrial malfunction, synaptic damage, and the resultant impairment in cognitive 
function are pathological features of diabetes-affected brains.2 Diabetes adversely affects the 
brain and increases the risk for depression and dementia.29–39 In neurons, synaptic 
mitochondria are vital for the maintenance of synaptic function and transmission through 
normal mitochondrial dynamics, distribution, and trafficking as well as energy metabolism 
and synaptic calcium modulation. Imbalance of mitochondrial dynamics contributes to 
oxidative stress and hyperglycemia-induced alterations in mitochondrial morphology and 
function.38,40,41 Diabetes elicits AD-like brain changes linked with cognitive decline and 
neurodegeneration, such as elevated tau expression and phosphorylation and accumulation 
of Aβ,42–46 mitochondrial dysfunction, disruption of mitochondrial dynamics,37,38,41,47–51 
oxidative stress,40,49 neuroinflammation, loss of synapses, impaired learning and memory, 
and synaptic plasticity deficits.29,35,36,44,52–55 The underlying mechanisms and strategies to 
rescue such injury and dysfunction are not well understood. Studies have identified several 
cellular and mitochondrial cofactors that are directly or indirectly involved in AD- and 
diabetes-mediated alterations in mitochondrial and synaptic structure and function. Such 
factors include cyclophilin D (CypD), presequence protease (PreP), Aβ, mPTP, N-methyl-D-
aspartate, and the receptor for advanced glycation endproducts (RAGE).
This chapter addresses several aspects of AD- and diabetes-induced mitochondrial 
dysfunction with a special focus on mitochondrial molecular mechanisms underlying 
synaptic pathology and cognitive dysfunction.
2. MITOCHONDRIAL FUNCTION
Mitochondria are essential organelles for cell survival, playing a crucial role in calcium 
homeostasis, energy metabolism, detoxification of ROS generation, and induction of cell 
death, including apoptosis and necrosis. Mitochondria in different types of cells or in 
different subcompartments of one cell differ significantly in their morphology and function 
and can be divided into multiple subgroups within one cell.56 The recent recognition of 
mitochondrial heterogeneity facilitates our understanding of mitochondrial biology.
Mitochondria are the major site of ATP synthesis and are also the site of amino acid 
biosynthesis, fatty acid oxidation, steroid metabolism, calcium homeostasis, and ROS 
production and detoxification. The inner mitochondrial membrane is largely impermeable 
and contains a variety of enzymes, including those responsible for making ATP, and forms 
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the major barrier between the cytosol and the mitochondrial matrix. The five complexes of 
the respiratory chain [complex I (NADH ubiquinone oxidoreductase), complex II (succinate 
ubiquinone oxidoreductase), complex III (ubiquinone-cytochrome c reductase), complex IV 
(cytochrome oxidase), and complex V (ATP synthase)] are embedded in the inner 
mitochondrial membrane. The transmission of electrons along the respiratory chain provides 
the energy to pump protons from the matrix into the intermembrane space, thereby 
generating the electrochemical gradient required to drive ATP synthesis.56
3. SYNAPTIC MITOCHONDRIAL PATHOLOGY IN AD
Synapses are the neuronal contact sites through which neurons receive and send information.
57,58 Energy provision and calcium fluctuation in synapses are prerequisite for interneuronal 
communication.59 To meet the high energy demands and to cope with constant calcium flux, 
synapses are enriched with mitochondria for on-site energy provision and calcium 
modulation.60
Although the detrimental impacts of Aβ on synapses and synaptic function are extensive, 
multiple studies demonstrate that mitochondrial structure and function are particularly 
susceptible to the effects of mitochondrial Aβ accumulation.7–28 Further, synaptic 
mitochondria serve as a reservoir for Aβ accumulation in aging and AD1,5,61–64; thus 
mitochondrial dysfunction is a major player in the synaptic alterations seen in AD and 
diabetes.3,56,65
First, mitochondrial and neuronal malfunction in AD is linked to the progress accumulation 
of Aβ in the mitochondria of both human AD and transgenic AD mouse brains.
1,7–9,11,15–18,66–68 Aβ can directly import into mitochondria via the translocase of the outer 
membrane machinery,67 RAGE,69 or other unknown mechanisms. Aβ may also be locally 
produced in mitochondria via gamma-secretase that is localized in mitochondria.70–72 
Notably, accumulation of mitochondrial Aβ precedes extracellular Aβ deposition in AD 
brains, increases with age, and associates with early onset synaptic loss, synaptic damage, 
and mitochondrial oxidative damage,5,7,10,11,22,73–83 suggesting that early accumulation of 
Aβ in mitochondria may be an initiating pathological event, leading to mitochondrial and 
neuronal perturbation. Second, interaction of Aβ with mitochondrial matrix proteins such as 
amyloid-binding alcohol dehydrogenase (ABAD)7,10,11,84 and CypD23,85–87 exacerbates 
Aβ-induced mitochondrial and neuronal stress. Increasing PreP activity by antagonizing the 
Aβ-ABAD interaction decreases mitochondrial and cerebral Aβ accumulation in AD mice 
overexpressing Aβ and improves mitochondrial function.88 Third, increasing neuronal PreP 
expression and activity in Aβ-enriched synaptic mitochondria of mAPP mice greatly reduces 
mitochondrial accumulation. Accordingly, synaptic function and learning and memory are 
significantly improved in PreP-overexpressed mitochondria.28 These data strongly indicate 
that PreP is critical for maintaining mitochondrial integrity and function by clearance of 
mitochondrial Aβ. Strategies that reduce Aβ levels in mitochondria in addition to the brain 
by increasing PreP expression and activity are critical to consider as new avenues for both 
preventing and halting AD progression at the early stage. One such therapeutic strategy 
involves the development of a small-molecule agonist of PreP in order to safely decrease 
mitochondrial and cerebral Aβ accumulation by accelerating Aβ clearance.
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These recent studies highlight the significant role of Aβ in synaptic mitochondrial pathology 
and significantly advance our understanding of the mechanisms underlying mitochondrial 
dysfunction in AD, especially in the early stage when the presence of Aβ has not yet set in 
motion the devastating cognitive impairments often associated with AD. Ameliorating 
alterations in mitochondrial function could improve synaptic function and reverse cognitive 
decline in AD.
In AD and non-AD cell and animal models, treatment of mitochondria-targeted molecules 
mitoQ and SS31 significantly reverses Aβ-induced CypD elevation, mitochondrial fusion/
fission proteins imbalance, and neurite growth.89 MitoQ and SS31 also reduce mutant 
huntingtin-induced mitochondrial toxicity and synaptic damage.90 Additionally, antioxidants 
attenuate mitochondrial transport and function in cybrid cells containing AD-derived 
mitochondria.4,91 These results suggest a close relationship between neuronal mitochondrial 
dysfunction and synaptic perturbation and the value of eliminating neuronal mitochondrial 
oxidative stress in the treatment of neuronal/synaptic alterations in AD.1,90
4. IMPACT OF CypD-DEPENDENT mPTP ON MITOCHONDRIAL DEFECTS
CypD is a crucial component of the mPTP. CypD released from matrix can bind to the 
adenine nucleotide translocase in the inner mitochondrial membrane and the voltage-
dependent anion channel in the outer mitochondrial membrane to trigger the opening of 
mPTP, a nonselective, high conductance pore allowing the transport not only calcium but 
any solute below the pore size. The opening of mPTP results in osmotic swelling, dissipation 
of the mitochondrial membrane potential, reduced mitochondrial calcium retention capacity, 
decreased membrane potential, increased ROS production, and eventually, cell death (Fig. 
1).92 Increased expression of CypD occurs in neurodegenerative diseases including AD, 
Parkinson’s disease (PD), Huntington’s disease (HD),23,87,93–97 and diabetes, and con 
tributes to mitochondrial perturbation.5,23,65,98
Studies from in vitro cellular and in vivo animal models have demonstrated that blockade of 
CypD significantly attenuates mPTP-related mitochondrial dysfunction and cell death, 
which are relevant to the pathogenesis of stroke, AD, and diabetes.23,65,87,98–102 
Furthermore, blockade of mPTP by genetic depletion or pharmacological inhibition of CypD 
rescues axonal mitochondrial trafficking and protects synapses from Aβ toxicity. The 
potential mechanisms underlying the protective effect of CypD deficiency on axonal 
mitochondrial trafficking include the reduction of Aβ-induced calcium perturbation, the 
suppression of axonal ROS accumulation, and the activation of the downstream P38/MAPK 
signaling pathway.
The protein kinase A/cAMP regulatory element-binding (PKA/CREB) signaling pathway, a 
crucial regulator of synaptic plasticity and learning memory, is adversely affected by an Aβ-
rich environment, leading to dendritic spine architecture changes in an AD mouse model.102 
Aβ reduces phosphorylation of PKA, thus disrupting PKA/CREB signal transduction and 
causing synaptic and cognitive dysfunction.100,102 Notably, neurons lacking CypD reverse 
Aβ-induced synaptic dysfunction and are protected against Aβ-induced alterations in PKA 
and CREB phosphorylation. These results indicate the involvement of CypD in Aβ-induced 
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abnormalities in signal transduction including PKA/CREB signaling. Sustained CypD-
induced neuronal/synaptic mitochondrial stress is a potential mechanism underlying synaptic 
failure in the pathogenesis of AD.
Recently, Wang et al. demonstrated that CypD expression levels were significantly elevated 
in the hippocampi of streptozotocin-induced diabetic mice.56 The CypD expression levels 
are further elevated in Aβ-enriched diabetic brain compared to nondiabetic mAPP mice.56 
These results suggest that CypD expression is increased in diabetes mellitus and further 
enhanced in an Aβ-rich environment. Increased levels of CypD in mitochondria trigger/
enhance the mPTP opening, leading to colloidal osmotic swelling of the mitochondrial 
matrix, dissipation of the inner membrane potential, generation of ROS, and release of many 
proapoptogenic proteins and procaspases.99 Hence, blockade of CypD may be a potential 
therapeutic strategy for preventing and halting synaptic and mitochondrial pathology in AD. 
Specifically, the development of small-molecule CypD inhibitors could hold therapeutic 
potential for the treatment of neurodegenerative diseases including AD and diabetes.103,104
5. EFFECT OF NEURONAL PreP ACTIVITY AND RAGE SIGNALING ON 
MITOCHONDRIAL DYSFUNCTION
PreP is a mitochondrial peptidasome that is localized in the mammalian mitochondrial 
matrix.105 It is the key for maintenance of mitochondrial health and integrity. PreP 
proteolytic activity is significantly reduced in AD-affected brain mitochondria and 
transgenic AD mouse models106 and is negatively correlated to mitochondrial Aβ 
accumulation. Du et al. demonstrated that increased expression and activity of neuronal PreP 
significantly reduced mitochondrial Aβ load and the production of proinflammatory 
mediators, improved mitochondrial function and synaptic plasticity, and attenuated cognitive 
decline in AD mice.28 Furthermore, PreP proteolytic activity is required for degradation and 
clearance of mitochondrial Aβ. Mitochondrial Aβ accumulation may interfere with normal 
mitophagy and release of mitochondria-derived damage-associated molecular patterns from 
the injured neurons, leading to increased production of TNF-α, IL-1β, and MCP1, the 
cytokines known to be involved in the inflammatory process of AD.107 Thus, dysfunctional 
or damaged mitochondria can produce excessive inflammation and tissue damage possibly 
via overproduction of cytokines and ROS.
RAGE-dependent signal transduction via Aβ-RAGE interaction plays an important role in 
mitochondrial dysfunction. RAGE serves as an important cell-surface receptor mediating 
chemotactic and inflammatory reaction to Aβ and other proinflammatory ligands.69,108–113 
RAGE signaling in neurons and microglia is known to promote induction of 
proinflammatory mediators, including cytokines and chemokines, and activation of 
microglia by increased expression of microglial markers (CD4 and CD11).107,110 
Additionally, over-expression of neuronal PreP in mAPP mice not only reduces Aβ 
accumulation in the brain but also remarkably suppresses RAGE expression as compared 
with mAPP mice,69 suggesting a possible connection between mitochondrial defects and 
RAGE signaling relevant to the activation of transcription and the proinflammatory 
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response.28,69,107,109,110,112 Further investigation is required to elucidate the role of RAGE 
in mitochondrial dysfunction relevant to the pathogenesis of AD and diabetes.
6. EFFECTS OF METHIONINE SULFOXIDE REDUCTASE ON Aβ SOLUBILITY 
AND MITOCHONDRIAL FUNCTION
Accumulation of oxidized proteins, especially Aβ, is thought to be one of the common 
causes of AD. Induced ROS generation is one of the earliest consequences of toxic insults 
mediated by soluble Aβ oligomers.81 Mitochondria are particularly sensitive to ROS, and 
reduced metabolic activity resulting from oxidative damage to vital mitochondrial 
components has been demonstrated in AD.10
Methionine (Met) is highly susceptible to oxidation in vivo, particularly under conditions of 
oxidative stress. The sulfoxide form comprises 10%–50% of Aβ in amyloid plaques of AD 
brain.114 Oxidation of Met to Met(O) is reversible and the reverse reaction is catalyzed in 
vivo by the methionine sulfoxide reductase (Msr) system, composed of peptide-methionine 
(S)-S-oxide reductase (MsrA) and peptide-methionine (R)-S-oxide reductase (MsrB), which, 
respectively, reduce the S and R enantiomers of the sulfoxide group. These enzymes provide 
both an efficient repair mechanism for oxidative damage to Met residues and general 
protection against oxidative stress by scavenging ROS through the recycling of Met.
Studies from primary hippocampal and cortical neurons show increased total Msr activity, 
ascribed to increased activity in both MsrA and MsrB, in conjunction with protection against 
cell death induced by the sulfoxide forms of Aβ40 or Aβ42. Exposure of wild-type and 
MsrA knockout mouse cortical neurons to Aβ42 and Met(O)-Aβ demonstrated that lack of 
MsrA abolishes the protective effect induced by Met(O)-Aβ.115 Furthermore, lack of MsrA 
promotes a shift from aggregated forms of Aβ toward soluble oligomers. Given that soluble 
oligomer Aβ are thought to be more toxic to neurons and synapses than aggregated Aβ 
forms,115 enhancing MsrA activity by regulating transcription may have therapeutic 
applications. Alterations in MsrA expression levels and Aβ structure during normal aging 
might be a cofactor in AD-related mitochondrial malfunction.115
7. IMPACT OF MITOCHONDRIAL DYNAMICS IN MCI AND AD
Mitochondria are highly dynamic organelles that undergo continuous fission and fusion, 
which are regulated by the GTPase hydrolysis activity mitochondrial fission proteins (DLP1 
and Fis1) and mitochondrial fusion protein [mitofusin 1 and 2 (Mfn1 and 2) and optic 
atrophy (Opa1)]. Mitochondrial dynamics are important for the proper distribution of 
mitochondria within cells, which is particularly critical for morphologically complex cells 
such as neurons.116 Alterations in mitochondrial dynamics significantly impact almost all 
aspects of mitochondrial function including energy metabolism, calcium buffering, ROS 
generation, and apoptosis regulation.117,118 Unbalanced fusion and fission lead, respectively, 
to mitochondrial elongation and excessive mitochondrial fragmentation, both of which 
impair the function of mitochondria. It has been shown that exchange of mitochondrial 
contents is important for mitochondrial function as well as organelle distribution in neurons. 
Mitochondrial fusion, in particular that mediated by Mfn2, is required for proper 
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development and maintenance of the cerebellum.119 Mutations in the Mfn2 gene cause 
neurodegenerative diseases, such as Charcot–Marie–Tooth type 2A, and mutations in OPA1 
cause dominantly inherited optic atrophy. Increasing evidence implicates altered 
mitochondrial trafficking and fusion–fission dynamics in aging-related AD, PD, HD, and 
amyotrophic lateral sclerosis.
7.1 Effect of Mfn2 on Mitochondrial Function
Mitofusins Mfn1 and Mfn2 are outer membrane GTPases that mediate outer mitochondrial 
membrane fusion. Mfn2 expression is crucial for maintaining the morphology and operation 
of the mitochondrial network and mitochondrial metabolism. Recent studies demonstrate 
that markedly reduced mitochondrial mass and transport may contribute to neuronal loss due 
to the specific loss of Mfn2 but not Mfn1.120 Du et al. examined the role of Mfn2 in the 
human-induced pluripotent stem cells (hiPSCs) differentiation system and reported that 
knockdown of Mfn2 results in mitochondrial dysfunctions and defects in neurogenesis and 
synapse formation.119 By contrast, Mfn2 overexpression in neural progenitor cells directs 
differentiation and maturation into neurons with enhanced mitochondrial functions, 
suggesting that Mfn2 is crucial for mitochondrial development, and thereby essential to 
hiPSCs differentiation. Importantly, this also provides a novel neurophysiologic model of 
mitochondrial development in neurogenesis, which enhances our understanding of the 
involvement of dysfunctional mitochondria in aging and neurodegenerative diseases.119 
Under pathological conditions, Mfn2 expression levels are increased such as mild cognitive 
impairment (MCI)-derived mitochondria, leading to aberrant mitochondrial fusion and 
fission event evidenced by abnormal mitochondrial morphology and function.
7.2 Oxidative Stress and MCI- and AD-Related Mitochondrial Dynamics
MCI is characterized by a decline in cognitive abilities that is noticeable yet not severe 
enough to completely disrupt an individual’s daily activity. MCI is generally considered to 
be a transitional phase between normal aging and early dementing disorders, especially AD.
121
In cybrid model, MCI-induced mitochondrial defects manifest as alterations in 
mitochondrial dynamics, function, and morphology. These dysfunctional MCI cybrid 
mitochondria exhibit impaired fission/fusion events, impaired mitochondrial respiratory 
chain enzyme activity, decreased membrane potential, increased mitochondrial and 
intracellular ROS, and impairment in energy metabolism with decreased ATP levels when 
compared to non-MCI cybrid mitochondria. Given that mitochondrial Mfn2 is involved in 
mitochondrial fusion,119 increased mitochondrial Mfn2 levels in MCI cybrids suggest that 
altered Mfn2 expression likely contributes to enhanced mitochondrial fusion. Accordingly, 
changes in MCI mitochondrial morphology display as elongated mitochondria. Interestingly, 
suppression of Mfn2 overexpression by inhibiting oxidative stress-mediated activation of 
extracellular signal-regulated kinases (ERK) reverses abnormalities in mitochondrial 
structure and function.122 Thus, generation of Mfn2 antagonist may hold potential for 
prevention and treatment at the early stage of AD.123
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In contrast to MCI-derived mitochondria, AD mitochondria exhibit fragmentation as shown 
by overabundant fission, elongate, and aggregated mitochondria, compared to cybrid cells 
containing mitochondria from normal age-matched subjects with the relatively normal 
cognitive function. DLP1, which plays a key role in balancing mitochondrial dynamics by 
regulating mitochondrial fission, was significantly increased in AD mitochondria.123 
Additionally, the abnormal interaction of DLP1 with hyperphosphorylated tau was found in 
AD neurons.124 Interaction of DLP1 with glycogen synthase kinase-3 (GSK3β) mediates 
changes in mitochondrial morphology and dynamics.125–127 Mitochondrial dynamics 
modulates the induction of proinflammatory mediators in microglial cells.128,129 ROS-
induced activation of the mitogen-activated protein (MAP) kinase family appears to play a 
key role in mediating cellular responses to multiple stresses. ERK signaling is involved in 
mitochondrial function and neuronal stress.123,130 Taken together, this suggests that 
oxidative stress-induced activation of MAP kinase via upregulation of DLP1 or Mfn2 
expression contributes to mitochondrial dysfunction and abnormal mitochondrial 
dynamics122,123 by disrupting the balance of mitochondrial fission and fusion and promoting 
translocation of DLP1 to mitochondria, leading to mitochondrial fragmentation in AD. Most 
importantly, suppression of ERK signaling and inhibition of mitochondrial fission or fusion 
pathways rescues defective mitochondrial morphology and function induced by AD or 
MCI123 (Fig. 2). Antioxidant treatment attenuates AD mitochondrial defects, leading to 
improvements in axonal mitochondrial transport and mitochondrial bioenergy and function.
4,91
8. DRP1-MEDIATED MITOCHONDRIAL ABNORMALITIES IN DIABETES
Mitochondria are dynamic organelles that undergo continuous fission and fusion. Fission 
events are regulated by dynamin-related protein (Drp1), while fusion events are regulated by 
the large dynamin-related GTPases known as Mfn1 and Mfn2 as well as optic atrophy 1 
(OPA1).131 Alterations in mitochondrial dynamics affect mitochondrial numbers and shape, 
respiratory enzyme activity, and ATP production. Imbalance between mitochondrial fission 
and fusion in diabetes results predominantly from upregulation of Drp1, which induces 
mitochondrial dysfunction (impaired respiration and ATP production) in a variety of cell 
types, including dorsal root ganglion neurons and β cells.41 Mitochondrial dysfunction has 
been implicated in the development of insulin resistance in skeletal muscle cells and 
hyperglycemia.132
A novel and pivotal role of mitochondrial dysfunction in diabetes-induced synaptic 
impairment involves a GSK3b/Drp1-dependent connection between mitochondrial 
dysfunction in diabetic neurons and synaptic dysfunction including decline in long-term 
potentiation. These findings are consistent with diabetic neuropathy as shown by increased 
Drp1 expression and mitochondrial fission in dorsal root ganglion neurons of 6-month-old 
type II diabetes (db/db) mice.2 In contrast to the greater numbers of mitochondria in dorsal 
root ganglion neurons, hippocampal neurons in 5- to 6-month-old db/db mice displayed 
smaller numbers of mitochondria, such a decrease was not seen in mice younger than 3 
months. Between 3 and 6 months of age, complex I enzyme activity significantly declined 
by 15%–35% and ATP content was significantly altered. Pharmacologic or genetic 
inactivation of Drp1 prevented changes in mitochondrial morphology and function in db/db 
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mouse hippocampus or human neuronal cells under hyperglycemic conditions, indicating the 
role of Drp1 in diabetes-induced mitochondrial dysfunction.2 Furthermore, genetic 
activation of GSK3β without high glucose treatment can also promote mitochondrial 
fragmentation, while inactivation of GSK3β prevents high glucose-induced mitochondrial 
dysfunction. Taken together, these data suggest that GSK3β likely acts as an upstream 
signaling mechanism for Drp1 upregulation in diabetes-induced mitochondrial dysfunction.2
9. CONCLUSION
Several lines of evidence suggest that age-related AD and diabetes are predominantly 
associated with mitochondrial dysfunction. Mitochondrial defects result in increased ROS 
generation, abnormal protein–protein interactions, and decreased mitochondrial ATP 
production. Overproduction of ROS and mPTP formation with attendant compromised 
mitochondrial function contribute importantly to neuronal perturbation. Several other factors 
including intracellular Ca2+, Aβ, and CypD also play an important role in mPTP formation, 
leading to mitochondrial dysfunction. In addition, disruption of mitochondrial dynamics by 
altered mitochondrial fusion and fission events contributes to mitochondrial and synaptic 
injury and cognitive decline relevant to the pathogenesis of AD and diabetes (Fig. 3). Thus, 
inhibition of mPTP opening by blocking CypD and regulation of mitochondrial dynamics 
are rational targets for potential therapeutic strategies for AD and diabetes.
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Effect of Aβ on CypD-involved mPTP formation. Aβ-cyclophilin D interaction mediates 
impairments in axonal mitochondrial transport due to an increase in the opening of CypD-
mediated mitochondrial permeability transition pore (mPTP). This leads to the disruption of 
Ca2+ balance and increases the production/accumulation of reactive oxygen species (ROS). 
Elevation of Ca2+ and oxidative stress activates the downstream p38 MAP kinase signaling 
pathway, thus contributing to mitochondrial dysfunction.
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Effect of AD on mitochondrial dynamics. AD-induced mitochondrial respiratory function 
abnormality orchestrates ROS generation and accumulation and subsequently activates ERK 
signal transduction. Activation of ERK signaling disrupts mitochondrial dynamics and 
results in altered DLP1 and Mfn2 expression, which eventually leads to mitochondrial 
dysfunction. Inhibition of DLP1 or Mfn2 expression attenuates AD- or MCI-derived 
mitochondrial and neuronal dysfunction (Mdivi-1, an inhibitor for DLP1).
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The cellular factors and related pathways contribute to Aβ-mediated mitochondrial defects 
and synaptic damage. Aβ accumulation perturbs mitochondrial transport and dynamics, cell 
signaling, synaptic mitochondrial structure and function, leading to decreased energy 
metabolism/ATP production, deregulation of calcium homeostasis, perturbed cell signaling 
cascades, altered key enzymes associated with mitochondrial respiratory chain, induced 
oxidative stress, and, eventually, synaptic injury and cognitive decline.
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